GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders…
$19.10+3.30%
报价 2026-11-13
市值
$1.31B
EV
$573.7M
PE (TTM)
–
预期 PE
–
52 周区间距高点 -37.7%
$12.49$30.64
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| GHRSGH Research PLC | $1.31B | +3.3% | – | 0% | – | – | – | |
| AAPGASCENTAGE PHARMA GROUP INTERNATIONAL | $1.36B | -2.7% | – | 81.6% | – | – | – | |
| MLYSMineralys Therapeutics, Inc. | $1.36B | -1.1% | – | 0% | – | – | – | |
| INVAInnoviva, Inc. | $1.35B | +0.3% | +9.6% | 78.9% | 6.0x | 3.0x | 7.5x | |
| DMRAGalecto, Inc. | $1.34B | -2.0% | – | 0% | – | – | – | |
| TSHATaysha Gene Therapies, Inc. | $1.33B | -2.6% | -67.8% | 94% | – | – | – | |
| MNKDMannKind Corporation | $1.33B | -0.7% | +26.9% | 75.7% | – | 49.6x | – | |
| URGNUroGen Pharma Ltd. | $1.28B | -0.8% | +185.5% | 90.9% | – | – | – | |
| OMEROmeros Corporation | $1.27B | -2.8% | +5000.0% | 95.8% | 9.7x | 10.7x | – | |
| 同行中位数 | – | – | +26.9% | 80.2% | 7.8x | 10.7x | 7.5x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。